Update on Neuroimaging Techniques to Detect Activity and Progression in MS: The Role of Novel Markers for Chronic Active Inflammation (PRLs, SELs)
•The central vein sign could be used for differential diagnosis.
•PRLs appear in the early stages and are more common in inflammatory stages.
•PRLs are related to more aggressive disease
•Brain atrophy assessed could help us to assess progression
•Smouldering MS and progressive MS can be imaged using classic and novel techniques
•SELs are related to progressive phases of the disease
BIOGRAPHY
CELIA OREJA-GUEVARA
Prof. Celia Oreja-Guevara is Vice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos, Madrid and Professor of Neurology at the University Complutense, Madrid, Spain.
After receiving her MD from the University Complutense, Madrid, Professor Oreja-Guevara completed a PhD in neuroimmunology at the Max-Planck-Institute for Neurobiology, University of Munich, Munich (Germany). She then went on to complete a residency in the Department of Neurology at the University of Bochum, Bochum (Germany) and a postdoctoral fellowship in neuroimaging at the University Hospital San Raffaele, Milan (Italy). She has also held posts at the University of Düsseldorf (Germany),Hospital de Fuenlabrada and at the University Hospital La Paz, both in Madrid.
Professor Oreja-Guevara’s research interests centre on family planning, menopause, clinical and neuroimaging correlations in MS and the use of optical coherence tomography. Neuromyelitis optica (NMO) is among her other therapy areas of interest, and Professor Oreja-Guevara is actively involved in the evaluation of new drugs for the treatment of MS and NMO. As an investigator, she has participated in a number of MS clinical trials and currently heads Paradigms, an independent and non-profit international group of Multiple Sclerosis experts. Currently, Professor Oreja-Guevara is an expert for the Spanish Medicines Agency and for the Scientific Advisory Group on Neurology of the European Medicines Agency.